This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 7, 2013 /PRNewswire/ -- The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence. The 81-page document represents an intensive collaboration among experts in the radiation oncology and urology fields, led by
Richard K. Valicenti, MD, MA, professor and chair of the department of radiation oncology at the
University of California Davis Comprehensive Cancer Center in
Sacramento, on behalf of ASTRO, and
Ian M. Thompson, MD, director of the Cancer Therapy and Research Center at the
University of Texas Health Science Center at
San Antonio and the Glenda and Gary Woods Distinguished Chair in genitourinary oncology, on behalf of the AUA.
The Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline is a comprehensive review of 324 research articles of English-language publications within the Pubmed, Embase and
Cochrane databases, published from
January 1, 1990 through
December 15, 2012. The guideline is available online free as a PDF document at
www.auanet.org, and will be published in the
August 1, 2013, print issue of the
International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of ASTRO, and in the
August 2013 print issue of
The Journal of Urology, the official journal of the AUA.
The strategies and approaches recommended were derived from evidence-based and consensus-based processes in the reviewed articles. The systematic review included articles that provided detailed efficacy in patients with detectable and undetectable prostatic specific antigen (PSA) levels, toxicity and quality of life impact, and optimal imaging strategies to determine the appropriateness of radiation therapy use in patients suspected of recurrence. Only studies in which PSA data were provided for 75 percent or more patients were included in the guideline.